Dayvigo Sexual Function Impact: What the Evidence Actually Shows

Why Orexin Biology Matters for Sexual Function

Orexin neuropeptides (orexin-A and orexin-B, also called hypocretin-1 and hypocretin-2) are produced in the lateral hypothalamus and project widely across the brain. Their receptors, OX1R and OX2R, are expressed not only in arousal circuits but also in the hypothalamic paraventricular nucleus and the medial preoptic area, regions that coordinate reproductive hormone release [1].

Orexin and the HPG Axis

Animal data published in the Journal of Neuroendocrinology show that intracerebroventricular orexin-A stimulates luteinizing hormone (LH) pulsatility through gonadotropin-releasing hormone (GnRH) interneurons [2]. Blocking this signaling pharmacologically raises the question of whether a dual orexin receptor antagonist could blunt LH amplitude and, downstream, testosterone or estradiol production.

The short answer at clinical doses appears to be: probably not meaningfully. Lemborexant binds OX1R and OX2R competitively and reversibly, with binding offset occurring as plasma concentrations fall during the second half of sleep [3]. The receptor occupancy at the hypothalamic-pituitary interface during waking hours, when gonadotropin pulses are most physiologically relevant, is expected to be low given lemborexant's mean terminal half-life of approximately 17 to 19 hours and its concentration-dependent receptor kinetics [4].

OX2R, GnRH Pulsatility, and Sleep Architecture

Sleep itself is the dominant driver of nocturnal LH pulsatility in men, and restorative sleep correlates positively with morning testosterone levels [5]. A drug that consolidates sleep without suppressing slow-wave or REM architecture could therefore support, rather than impair, the hormonal environment relevant to sexual function. SUNRISE-1 (N=1,006) demonstrated that lemborexant 5 mg and 10 mg both improved polysomnography-measured sleep onset latency and wake after sleep onset versus placebo without producing the REM suppression characteristic of benzodiazepine receptor agonists [6].

SUNRISE-1 Trial Data and Adverse Event Reporting

SUNRISE-1 was a 12-month, randomized, double-blind, placebo- and active-controlled (zolpidem ER 6.25 mg) trial published in JAMA Network Open in 2019 (N=1,006, ages 18 to 88 years) [6]. The co-primary endpoints were subjective latency to sleep onset (sLSOT) and subjective wake after sleep onset (sWASO) at months 1, 3, and 6.

Sexual Adverse Events in the Published Safety Profile

The published safety table in SUNRISE-1 does not list sexual dysfunction, decreased libido, anorgasmia, or erectile dysfunction as treatment-emergent adverse events occurring at a frequency that crossed the reporting threshold (generally 2% or greater in industry-sponsored insomnia trials) [6]. The FDA prescribing information for lemborexant similarly omits sexual adverse events from the labeled adverse reactions section, which lists somnolence (10 to 11% at 10 mg versus 6% placebo) and headache as the most common events [4].

This absence of signal differs meaningfully from the profile of some older agents. Zolpidem and other GABA-A positive allosteric modulators have been associated with blunted nocturnal testosterone secretion in men in observational data, though controlled trial data specifically isolating this effect remain sparse [7].

Next-Morning Function as a Proxy Indicator

Sexual function does not occur in isolation from general daytime functioning. In SUNRISE-1, lemborexant 5 mg outperformed zolpidem ER 6.25 mg on next-morning residual sleepiness scores (as measured by the Karolinska Sleepiness Scale) at week 1 and across the 12-month observation period [6]. Residual sedation is relevant because daytime fatigue independently predicts reduced sexual desire in both men and women across multiple validated surveys [8].

Comparing Lemborexant With Other Sleep Drug Classes

Benzodiazepines and GABA-A Modulators

Chronic benzodiazepine use is associated with reduced testosterone in men and diminished sexual responsiveness in women [9]. A 2023 systematic review in Sleep Medicine Reviews covering 14 observational studies found that long-term hypnotic use (primarily benzodiazepines and Z-drugs) correlated with self-reported sexual dysfunction in 18 to 34% of users, with effect sizes largest in men over 50 [10]. Lemborexant's mechanism bypasses GABA-A receptor modulation entirely, which removes one plausible pathway to androgen suppression.

Suvorexant, the First Approved DORA

Suvorexant (Belsomra), the first dual orexin receptor antagonist approved in the United States, reached the market in 2014. Its prescribing information similarly does not list sexual dysfunction as a labeled adverse reaction [11]. Post-marketing surveillance databases (FAERS) contain scattered case reports of decreased libido with suvorexant, but these reports lack denominator data and cannot establish causality. The parallel absence of a sexual dysfunction signal in both approved DORAs strengthens the inference that the drug class as a whole carries a low direct liability in this domain.

Sedating Antidepressants Used Off-Label for Sleep

Trazodone and mirtazapine are frequently prescribed off-label for insomnia. Both carry well-documented sexual function effects, trazodone through priapism risk and alpha-1 adrenergic blockade, mirtazapine through histamine-1 and alpha-2 antagonism that may reduce genital arousal [12]. Patients switching to lemborexant from these agents sometimes report subjective improvement in sexual function, though this observation is anecdotal and no head-to-head trial exists.

Orexin, Arousal, and the Neuroscience of Desire

Sexual desire and behavioral arousal share overlapping neural substrates. The ventral tegmental area (VTA), nucleus accumbens, and medial preoptic area all receive orexin projections and are implicated in both motivated behavior and sexual appetitive states [13]. Orexin-A administration in rodent models increases sexual motivation scores, and orexin knockout mice show reduced copulatory behavior [14].

These animal findings do not translate directly to clinical predictions for lemborexant. Receptor antagonism at sleep-inducing doses is partial and time-limited. The drug's purpose is to reduce hyperarousal at sleep onset, not to globally suppress the orexin system. Chronic total orexin deficiency, as seen in narcolepsy type 1, is associated with sexual dysfunction in some case series, but pharmacological antagonism at therapeutic doses produces a fundamentally different receptor occupancy profile [15].

What Clinicians Should Tell Patients

Patients asking specifically about lemborexant and libido deserve a direct answer. Current evidence gives no reason to expect worsening of sexual function, and the drug's sleep-consolidating effect may indirectly support sexual wellbeing through improved daytime energy and reduced fatigue. The caveat is that no phase 3 study has used the Female Sexual Function Index (FSFI) or the International Index of Erectile Function (IIEF) as an endpoint, so the absence of a signal in adverse event tables reflects the limits of how the trials were designed, not a definitive absence of any effect [16].

Clinicians should ask about sexual function at baseline before prescribing, particularly in patients who also have depression, cardiovascular disease, or low testosterone, since these conditions confound attribution if a complaint emerges later.

Hormonal Interactions: Testosterone, Estradiol, and Prolactin

Testosterone

No published pharmacokinetic/pharmacodynamic study has measured morning serum testosterone as a primary endpoint in men taking lemborexant. The FDA-approved label includes no hormone-related warnings [4]. Mechanistic reasoning, supported by the reversible binding kinetics and the absence of GABA-A activity, argues against clinically significant testosterone suppression. A reasonable clinical practice is to check a baseline morning total testosterone in men with existing hypogonadism risk before starting lemborexant, then recheck at 3 months if the patient reports any change in libido or erectile function.

Estradiol and Female Sexual Function

Women represent approximately 60% of insomnia patients in clinical practice [17]. SUNRISE-1 enrolled 65% female participants [6]. The orexin system interacts with estradiol through estrogen response elements on the prepro-orexin gene promoter, meaning that menopausal estrogen decline may itself reduce orexin tone and worsen sleep [18]. Lemborexant supplementing deficient orexin signaling in post-menopausal women is not the mechanism of action, but improved sleep continuity in this population could reduce cortisol burden and partially support sexual function indirectly.

Prolactin

Prolactin is the most common hormone directly disrupted by sleep medications. Dopamine-blocking agents raise prolactin and reduce desire. Lemborexant has no meaningful dopaminergic activity [4]. Prolactin-mediated sexual dysfunction is therefore not a pharmacologically plausible concern with this drug.

Special Populations

Older Adults

SUNRISE-2 (N=949) enrolled adults 60 years and older and ran for 12 months, with a 12-month extension [19]. In this population, sexual function concerns are prevalent but under-reported. The safety profile in SUNRISE-2 showed no emergence of sexual adverse events as a recognized signal even in the extension period [19]. Age-related declines in testosterone and estradiol make this population vulnerable to medication-induced sexual dysfunction, and the absence of a label warning in a geriatric-specific trial is clinically meaningful.

Patients With Comorbid Depression

Approximately 40% of insomnia patients have comorbid depressive symptoms [20]. Depression itself causes sexual dysfunction through reduced dopaminergic tone. If lemborexant improves sleep in a depressed patient, the downstream effect on sexual function is likely net positive, but it cannot be separated from the effect of improved sleep on depressive symptoms generally. Prescribers should document the Patient Health Questionnaire-9 (PHQ-9) score and ask about sexual function at baseline and follow-up visits.

Patients on Testosterone Replacement Therapy

No published drug interaction study has examined lemborexant in men on testosterone replacement therapy (TRT) or women on hormone therapy. CYP3A4 is the primary metabolic pathway for lemborexant [4]. TRT formulations do not meaningfully inhibit or induce CYP3A4, so a pharmacokinetic interaction is unlikely. Clinicians combining these therapies can reasonably proceed without dose adjustment while monitoring patient-reported sexual function at routine follow-up.

Practical Prescribing Guidance

Starting Dose and Titration

The FDA-approved starting dose is 5 mg at bedtime, within 30 minutes of planned sleep time [4]. Dose escalation to 10 mg is permitted if 5 mg is tolerated but provides insufficient sleep improvement. Patients asking about sexual function as a concern before starting should be counseled that 5 mg carries the lowest somnolence rate (7% versus 11% for 10 mg) and is the appropriate first-line dose [4].

Monitoring Protocol After Initiation

A reasonable monitoring schedule:

• Baseline: morning serum testosterone (men), PHQ-9, brief sexual function screen (one to two validated questions from IIEF or FSFI)
• Week 4: follow-up on sleep outcomes and daytime fatigue; ask about any change in sexual desire or function
• Month 3: repeat testosterone if baseline was borderline or if the patient reports a new complaint
• Month 6 and beyond: annual monitoring consistent with general insomnia management guidelines from the American Academy of Sleep Medicine [21]

When to Reconsider the Medication

If a patient reports new-onset decreased libido or erectile dysfunction after starting lemborexant and other causes have been excluded (new comorbidity, stressor, relationship change, concomitant medication), a four-to-six week washout trial can clarify attribution. The half-life of approximately 17 to 19 hours means steady-state is cleared within approximately five days at the lower dose [4].

Evidence Gaps and Future Research Directions

The single most important gap in the current literature is the absence of a prospective RCT using a validated sexual function instrument as a prespecified secondary endpoint. SUNRISE-1 and SUNRISE-2 used sleep-focused endpoints and standard safety reporting, which captures events occurring at 2% or greater frequency. A dedicated sexual function substudy in 200 to 400 patients over 12 weeks using the FSFI (women) and IIEF-5 (men) would be sufficient to generate a definitive answer with adequate statistical power.

Secondary gaps include:

• No published data on lemborexant in patients with hypogonadism receiving concurrent TRT
• No nocturnal LH pulsatility studies under lemborexant in humans
• No data in post-menopausal women using concurrent systemic hormone therapy
• No head-to-head data versus suvorexant on sexual function outcomes

The American Academy of Sleep Medicine's 2023 clinical practice guideline on pharmacological insomnia treatment recommends lemborexant as an effective option for sleep onset and maintenance but does not address sexual function outcomes, reflecting the same evidence gap [21].

As the prescribing information states: "The clinical significance of orexin receptor antagonism on hormonal axes in humans has not been formally studied in clinical trials" [4]. That statement frames the honest limits of current knowledge.